The head of the American Hospital Association attempted to defend consolidation. Members of a House Energy and Commerce subcommittee were unmoved.
Provider consolidation slammed in latest House affordability hearing Read More »
Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown.
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure Read More »
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy Read More »
Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data Read More »
Prime biotech buyout targets such as Revolution Medicines and BioCryst Pharmaceuticals have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.
Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension, casting doubt on the asset’s future prospects.
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail Read More »
Hay enfermedades que guardan sus secretos con una obstinación inesperadamente férrea. La epilepsia es una de ellas. Una minirrevisión de resultados de estudios, publicada recientemente en la revista académica Genomic Psychiatry, sintetiza el panorama en rápida expa …
Miles de variantes genéticas, muchas ocultas, intervienen en la epilepsia Read More »
In this episode of Denatured, you’ll listen to Viswa Colluru, CEO and founder of Enveda and Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. We speak about how AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases to garner investor interest.
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms Read More »
Las herramientas de inteligencia artificial (IA), con la IA generativa a la cabeza, se están expandiendo en diferentes esferas de la sociedad, entre ellas, el mercado laboral. En una investigación reciente, se han analizado las repercusiones que comienza a tener esta tecnología …
En la historia de la física del siglo XX hay nombres que redefinen nuestra comprensión del universo. Uno de ellos es el de Chen Ning Yang, cuya obra no solo cambió conceptos fundamentales, sino que también abrió nuevas puertas en campos tan diversos como la f&iacut …
